These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31824860)

  • 1. Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications.
    Ryan MJ; Bose R
    Front Oncol; 2019; 9():1287. PubMed ID: 31824860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics analysis reveals the
    Hsiao TH; Chiu YC; Shao YJ
    Transl Cancer Res; 2019 Aug; 8(4):1279-1288. PubMed ID: 35116870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
    Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
    J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
    Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
    Schweizer MT; Cheng HH; Tretiakova MS; Vakar-Lopez F; Klemfuss N; Konnick EQ; Mostaghel EA; Nelson PS; Yu EY; Montgomery B; True LD; Pritchard CC
    Oncotarget; 2016 Dec; 7(50):82504-82510. PubMed ID: 27756888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies for DNA repair-deficient prostate cancer.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk prostate cancer: a disease of genomic instability.
    Tapia-Laliena MA; Korzeniewski N; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Nov; 32(8):1101-7. PubMed ID: 24931269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
    Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
    Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES
    Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of mismatch repair deficiency in prostate cancer.
    Sedhom R; Antonarakis ES
    Future Oncol; 2019 Jul; 15(20):2395-2411. PubMed ID: 31237441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
    Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
    Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of
    Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
    Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.
    Schweizer MT; Antonarakis ES
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):785-795. PubMed ID: 29040258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
    Slootbeek PHJ; Tolmeijer SH; Mehra N; Schalken JA
    Crit Rev Clin Lab Sci; 2024 May; 61(3):178-204. PubMed ID: 37882463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
    Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
    J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
    Lanka SM; Zorko NA; Antonarakis ES; Barata PC
    Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.